Biotechnology · NASDAQ
Current Price
$91.19
Intrinsic Value
Use the calculator below to estimate
Run a PE ratio stock valuation on BioNTech SE with auto-filled earnings data, adjustable target PE, and instant fair value estimate.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Earnings Yield
-5.80%
ROE (TTM)
-6.0%
Based on trailing twelve-month data, BNTX has earnings per share of N/A and trades at a PE ratio of N/A. These are key inputs for stock valuation using the PE ratio method.
The trailing twelve-month PE ratio of BNTX is available in the calculator. This stock valuation metric shows how much investors pay per dollar of BioNTech SE's earnings. Use MiniValuator's PE ratio calculator for detailed analysis.
Whether BNTX is overvalued depends on comparing its PE ratio to industry peers, historical averages, and growth expectations. A PE ratio above the sector average may indicate overvaluation, but high-growth companies often justify higher PE ratios. Run a full stock valuation on MiniValuator to analyze.
To value BNTX using PE ratio: compare its current PE to the sector average, analyze the PEG ratio for growth-adjusted stock valuation, check historical PE ranges, and estimate fair value by multiplying target PE by EPS. MiniValuator's PE ratio calculator automates this analysis.
The PEG ratio of BNTX is available in the calculator. PEG ratio divides the PE ratio by the earnings growth rate — a PEG below 1.0 may suggest the stock is undervalued relative to its growth, making it a useful complementary stock valuation metric.
PE ratio provides quick relative stock valuation — how BNTX compares to peers. DCF provides absolute stock valuation — what the stock is worth based on projected cash flows. For comprehensive stock valuation, use both methods together. MiniValuator offers both PE and DCF calculators.
